Contemporary consensus proposal on criteria and classification of eosinophilic disorders and related syndromes - PubMed (original) (raw)

. 2012 Sep;130(3):607-612.e9.

doi: 10.1016/j.jaci.2012.02.019. Epub 2012 Mar 28.

Amy D Klion, Hans-Peter Horny, Florence Roufosse, Jason Gotlib, Peter F Weller, Andrzej Hellmann, Georgia Metzgeroth, Kristin M Leiferman, Michel Arock, Joseph H Butterfield, Wolfgang R Sperr, Karl Sotlar, Peter Vandenberghe, Torsten Haferlach, Hans-Uwe Simon, Andreas Reiter, Gerald J Gleich

Affiliations

Peter Valent et al. J Allergy Clin Immunol. 2012 Sep.

Abstract

Eosinophilia is an important indicator of various neoplastic and nonneoplastic conditions. Depending on the underlying disease and mechanisms, eosinophil infiltration can lead to organ dysfunction, clinical symptoms, or both. During the past 2 decades, several different classifications of eosinophilic disorders and related syndromes have been proposed in various fields of medicine. Although criteria and definitions are, in part, overlapping, no global consensus has been presented to date. The Year 2011 Working Conference on Eosinophil Disorders and Syndromes was organized to update and refine the criteria and definitions for eosinophilic disorders and to merge prior classifications in a contemporary multidisciplinary schema. A panel of experts from the fields of immunology, allergy, hematology, and pathology contributed to this project. The expert group agreed on unifying terminologies and criteria and a classification that delineates various forms of hypereosinophilia, including primary and secondary variants based on specific hematologic and immunologic conditions, and various forms of the hypereosinophilic syndrome. For patients in whom no underlying disease or hypereosinophilic syndrome is found, the term hypereosinophilia of undetermined significance is introduced. The proposed novel criteria, definitions, and terminologies should assist in daily practice, as well as in the preparation and conduct of clinical trials.

Copyright © 2012 American Academy of Allergy, Asthma & Immunology. Published by Mosby, Inc. All rights reserved.

PubMed Disclaimer

Conflict of interest statement

Disclosure of potential conflict of interest: P. Valent receives honoraria and research support from Novartis and Bristol-Myers Squibb. P. F. Weller has consultant arrangements with GlaxoSmithKline, receives research support from the National Institutes of Health, and is secretary-treasurer of the International Eosinophil Society. K. M. Leiferman receives royalties from the Mayo Foundation and is a scientific advisory member for the National Eczema Association. M. Arock receives honoraria from Novartis. T. Haferlach is part owner of the Munich Leukemia Laboratory. A. Reiter has consultant arrangements with and has received honoraria from Novartis Pharma. G. J. Gleich has consultant arrangements with GlaxoSmithKline, Ception, Cephalon, Teva, and Beiersdorf; receives grant support from GlaxoSmithKline, Novartis, and the University of Utah; receives royalties from Ception, Cephalon, Teva, and the Mayo Foundation; receives equities from Immune Design; is on the Board of Directors for the American Partnership for Eosinophilic Disorders; and has submitted patents for studies of eosinophil-associated diseases. The rest of the authors declare that they have no relevant conflicts of interest.

Similar articles

Cited by

References

    1. Gleich GJ, Leiferman KM. The hypereosinophilic syndromes: still more heterogeneity. Curr Opin Immunol. 2005;17:679–84. - PubMed
    1. Tefferi A, Patnaik MM, Pardanani A. Eosinophilia: secondary, clonal and idiopathic. Br J Haematol. 2006;133:468–92. - PubMed
    1. Bain BJ, Fletcher SH. Chronic eosinophilic leukemias and the myeloproliferative variant of the hypereosinophilic syndrome. Immunol Allergy Clin North Am. 2007;27:377–88. - PubMed
    1. Gleich GJ. Mechanisms of eosinophil-associated inflammation. J Allergy Clin Immunol. 2000;105:651–63. - PubMed
    1. Ackerman SJ, Bochner BS. Mechanisms of eosinophilia in the pathogenesis of hypereosinophilic disorders. Immunol Allergy Clin North Am. 2007;27:357–75. - PMC - PubMed

Publication types

MeSH terms

LinkOut - more resources